Cytochrome P450 omega hydroxylase

Cytochrome P450 omega hydroxylases, also termed Cytochrome P450 ω-hydroxylases, CYP450 omega hydroxylases, CYP450 ω-hydroxylases, CYP omega hydroxylase, CYP ω-hydroxylases, fatty acid omega hydroxylases, cytochrome P450 monooxygenases, and fatty acid monooxygenases, are a set of cytochrome P450-containing enzymes that catalyze the addition of a hydroxyl residue to a fatty acid Substrate (chemistry). The CYP omega hydroxylases are often referred to as monoxygenases; however, the monooxygenases are CYP450 enzymes that add a hydroxyl group to a wide range of xenobiotic (e.g. drugs, industrial toxins) and naturally occurring endobiotic (e.g. cholesterol) substrates, most of which are not fatty acids. The CYP450 omega hydroxylases are accordingly better viewed as a subset of monooxygenases that have the ability to hydroxylate fatty acids. While once regarded as functioning mainly in the catabolism of dietary fatty acids, the omega oxygenases are now considered critical in the production or break-down of fatty acid-derived mediators which are made by cells and act within their cells of origin as autocrine signaling agents or on nearby cells as paracrine signaling agents to regulate various functions such as blood pressure control and inflammation.

Action

The omega oxygenases metabolize fatty acids (RH) by adding a hydroxyl (OH) to their terminal (i.e. furthest from the fatty acids' carboxy residue) carbons; in the reaction, the two atoms of molecular oxygen(O₂[ are reduced to one hydroxyl group and one water (H₂O molecule) by the concomitant oxidation of NAD(P)H (see monooxygenase).^[1][2]

RH + O₂ + NADPH + H⁺ → ROH + H₂O + NADP⁺

Functions

CYP450 enzymes belong to a superfamily which in humans is composed of at least 57 CYPs; within this superfamily, members of six CYP4A subfamilies, (which are CYP4A, CYP4B, CYP4F, CYP4V, CYP4X, and CYP4z) possess ω-hydroxylase activity viz., CYP4A, CYP4B, and CYP4F^[3][4][5] CYP2U1 also possesses ω hydroxylase activity.^[6] These CYP ω-hydroxylases can be categorized into several groups based on their substrates and consequential function

• 1) The only member of the CYP4B subfamily, CYP4B1, shows a preference for ω-oxidizing short-chain fatty acids, i.e. fatty acids that are 7-9 carbons long; CYP4B1 is far more weakly expressed in humans than that expressed in other mammals that were tested.^[7] Subsequent to their ω-hydroxylation, these products are converted to their acylcarnitine derivatives and transferred to mitochondria for complete oxidized by beta oxidation (see also omega oxidation).^[8]
• 2) A member of the CYP4A subfamily, CYP4A11, preferentially ω-hydroxylate medium-chain fatty acids, i.e. fatty acids that are 10-16 carbons long; CYP4A11, CYP4F2, CYP4F3A, CYP4F3B, CYP4F11, CYP4V2, and CYP4Z1 also metabolize these fatty acids.^[9] Subsequent to their ω-hydroxylation, these products are converted to their acylcarnitine derivatives and transferred to mitochondria for complete oxidized by beta oxidation (see also omega oxidation). ^[10]
• 3) Members of the CYP4F family, i.e. CYPA11, CYP4F2, CYP4F3A, CYP4F3B, and CYP4F11, as well as CYP2U1 ω-hydroxylate long chain fatty acids, i.e. fatty acids that are 18 to 20 carbons long.^[11] These hydroxyl fatty acids are then serially metabolized by alcohol dehydrogenase, aldehyde dehydrogenase, and dicarboxylyl CoA synthetase to form their respective Coenzyme A (CoA)-bound dicarboxylic acids and transferred to peroxisomes where they may undergo chain shortening or, as acylcarnitine derivatives or free acids, transferred to mitochondria for complete beta oxidation. The chain-shortened products of peroxisome metabolism may also be converted to phospholipids, triglycerides, and cholesterol esters.^[12]
• 4) Members of the CYP4F family, i.e. CYP4F2 and CYP4F3B, ω-hydroxylate very long chain fatty acids, i.e. fatty acids that are 22 to 26 carbons long.^[13] These hydroxyl fatty acids are then serially metabolized by alcohol dehydrogenase, aldehyde dehydrogenase, and dicarboxylyl CoA synthetase to form their respective CoA-bound dicarboxylic acids and transferred to peroxisomes where they may undergo chain shortening or, as acylcarnitine derivatives or free acids, transferred to mitochondria for complete beta oxidation. The chain-shortened products of peroxisome metabolism may also be converted to phospholipids, triglycerides, and cholesterol esters.^[14]
• 5) CYP4F22 ω-hydroxylates extremely long very long chain fatty acids, i.e. fatty acids that are 28 or more carbons long. The ω-hydroxylation of these special fatty acids is critical to creating and maintaining the skins water barrier function; autosomal recessive inactivating mutations of CYP4F22 are associated with the Lamellar ichthyosis subtype of Congenital ichthyosiform erythrodema in humans.^[15]
• 6) CYP4F2, CYP4F3A, CYP4F3B, and CYP4F11 ω-hydroxylate leukotriene B4 and very probably 5-hydroxyeicosatetraenoic acid and 5-oxo-eicosatetraenoic acid.^[16] This hydroxylation greatly reduces the ability of these arachidonic acid metabolites to stimulate cells that mediate inflammation and allergic reactions and may thereby limit and contribute to the resolution of these innate immunity reactions.^[17][18] One or more of these CYPs also omega hydroxylate 12-hydroxyeicosatetraenoic acid, lipoxins, hepoxilins, and acylceramides^[19] and may thereby contribute to limiting there biological effects. (However, the 20-hydroxy metabolite of 12-hydroxyeicosatetraenoic acid proved able to contract coronary arteries.^[20])
• 7) CYP4A11, CYP4F2, CYP4F3B, CYP4F11, CYP4F12, CYP4V2, CYP2U1, and possibly CYP4Z1 metabolize arachidonic acid to 20-Hydroxyeicosatetraenoic acid (20-HETE).^[21][22] Animal and human tissue studies suggest that the CYP-dependent production of 20-HETE contributes to the regulation of blood pressure, the growth of certain cancers, and the metabolic syndrome while genetic studies on single nucleotide polymorphism in humans support roles for: a) CYP4F11-dependent 20-HETE production in the prevention of hypertension; b) CYP4F2-dependent 20-HETE production of 20-HETE in the prevention of hypertension, ischemic stroke, and myocardial infarction; and c) CYP2U1 in Hereditary spastic paraplegia, possibly by a 20-HETE-dependent mechanism in a small percentage of patients with this disease (see 20-Hydroxyeicosatetraenoic acid#Human studies). Some or possibly even all of these CYPs may also omega hydroxylate eicosapentaenoic acid (EPA) and [docosahexaenoic acid]] (DHA). 20-hydroxy EPA and 20-hydroxy-DHA do stimulate Peroxisome proliferator-activated receptor alpha but their range of biological activities have yet to be investigated.^[23]

References

1. Harayama S, Kok M, Neidle EL (1992). "Functional and evolutionary relationships among diverse oxygenases". Annu. Rev. Microbiol. 46: 565–601. doi:10.1146/annurev.mi.46.100192.003025. PMID 1444267.
2. Schreuder HA, van Berkel WJ, Eppink MH, Bunthol C (1999). "Phe161 and Arg166 variants of p-hydroxybenzoate hydroxylase. Implications for NADPH recognition and structural stability". FEBS Lett. 443 (3): 251–255. doi:10.1016/S0014-5793(98)01726-8. PMID 10025942.
3. Panigrahy D, Kaipainen A, Greene ER, Huang S (Dec 2010). "Cytochrome P450-derived eicosanoids: the neglected pathway in cancer". Cancer Metastasis Reviews 29 (4): 723–35. doi:10.1007/s10555-010-9264-x. PMC: 2962793. PMID 20941528.
4. Annu Rev Pharmacol Toxicol. 2005;45:413-38. Review. PMID 15822183
5. Annu Rev Pharmacol Toxicol. 2005;45:413-38. Review.PMID 15822183
6. J Biol Chem. 2004 Feb 20;279(8):6305-14
7. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27. ReviewPMID 26233909
8. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15.PMID 18433732
9. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27. ReviewPMID 26233909
10. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15. Review PMID 18433732
11. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15. Review PMID 18433732
12. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15. Review PMID 18433732
13. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15. Review PMID 18433732
14. Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15. Review PMID 18433732
15. J Dermatol Sci. 2015 Jul;79(1):4-9. doi: 10.1016/j.jdermsci.2015.04.009. Epub 2015 Apr 30. Review.PMID: 25982146
16. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27.PMID: 26233909
17. O'Flaherty JT, Wykle RL, Redman J, Samuel M, Thomas M.J Immunol. 1986 Nov 15;137(10):3277-83.
18. Biochim Biophys Acta. 2015 Apr;1851(4):340-55. doi: 10.1016/j.bbalip.2014.10.008. Epub 2014 Oct 29. Review.PMID: 25449650
19. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27.PMID: 26233909
20. Biochim Biophys Acta. 1996 Apr 19;1300(2):143-50
21. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27.PMID: 26233909
22. J Biol Chem. 2004 Feb 20;279(8):6305-14. Epub 2003 Dec 3
23. Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27.PMID: 26233909